Divi's Laboratories Limited (NSE:DIVISLAB)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients	105.60B	93.60B	78.45B	77.67B	89.60B
Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients Growth	12.82%	19.31%	1.00%	-13.31%	28.56%
Total	105.60B	93.60B	78.45B	77.67B	89.60B
Total Growth	12.82%	19.31%	1.00%	-13.31%	28.56%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
India	11.07B	9.84B	9.76B	10.38B
India Growth	12.50%	0.82%	-5.96%	13.75%
Other Countries	50.39B	47.89B	42.58B	59.17B
Other Countries Growth	5.22%	12.47%	-28.04%	26.48%
Switzerland	19.08B	10.25B	6.86B	-
Switzerland Growth	86.15%	49.42%	-	-
USA	13.06B	10.47B	18.47B	20.05B
USA Growth	24.74%	-43.31%	-7.87%	45.42%
Total	93.60B	78.45B	77.67B	89.60B
Total Growth	19.31%	1.00%	-13.31%	28.56%

Source: S&P Global Market Intelligence.